QBECO

Drug Profile

QBECO

Alternative Names: QBECO SSI

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Qu Biologics
  • Class Bacterial vaccines; Cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Crohn's disease; Ulcerative colitis
  • No development reported Colorectal cancer

Most Recent Events

  • 14 Aug 2017 Qu Biologics receives positive feedback from the US FDA in response to pre-IND meeting package for expansion of inflammatory bowel disease programme to the US
  • 02 Aug 2017 Interim efficacy data from a phase II trial in Ulcerative colitis released by Qu Biologics
  • 19 Apr 2017 Efficacy data from a phase I/IIb trial in Crohn’s disease released by Qu Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top